Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beta-lactam Intermittent versus Continuous Infusion and Combination Antibiotic Therapy in Sepsis
2019-002327-15Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2022
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ceftazidime, piperacillin + tazobactam, cefepime, ceftazidime + avibactam, ceftolozane + tazobactam and 2 more in sepsis, Healthcare-associated infection (HAI) and septic shock (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: 30-day all-cause mortality. Started Dec 2022; status: active.
02
Drugs
ceftazidimepiperacillin + tazobactamcefepimeceftazidime + avibactamceftolozane + tazobactam
03
Conditions
sepsisHealthcare-associated infection (HAI)septic shock
Beyond the preview
Go deeper on 2019-002327-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002327-15.